Evaluation of the prognostic value of 2005 St Gallen risk categories for operated breast cancers in Hong Kong

Breast

Volumn 17, Issue 1, 2008, Pages 58-63

  Yau, T K ^a   Soong, I S ^a   Chan, K ^a   Chang, A ^a   Sze, H ^a   Yeung, M W ^a   Tung, R ^a   Lau, S ^a   Lee, A ^a  

^a PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

Author keywords

Breast carcinoma; Hong Kong; Risk

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ARTICLE; ASIAN; BREAST CANCER; BREAST SURGERY; CANCER CLASSIFICATION; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CHINESE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HONG KONG; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; TUMOR VOLUME;

EID: 38949129190     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.06.007     Document Type: Article

References (27)

1. American Joint Committee on Cancer Staging. Manual for staging of cancer, 6th ed. Philadelphia: J.B. Lippincott; 2002.
2. Sobin L., and Wittekind C. TNM classification of malignant tumors. 6th ed. (2002), Wiley, New York
3. Olivotto I.A., Bajdik C.D., Ravdin P.M., et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23 (2005) 2716-2725
4. Goldhirsch A., Wood W.C., Gelber R.D., et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21 (2003) 3357-3365
5. Goldhirsch A., Glick J.H., Gelber R.D., et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann Oncol 16 (2005) 1569-1583
6. Ross J.S., Fletcher J.A., Linette G.P., et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8 (2003) 307-325
7. Press M.F., Bernstein L., Thomas P.A., et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15 (1997) 2894-2904
8. Yamauchi H., Stearns V., and Hayes D.F. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19 (2001) 2334-2356
9. Schoppmann S.F., Bayer G., Aumayr K., et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 240 (2004) 306-312
10. de Mascarel I., Bonichon F., and Durand M. Obviousl peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur J Cancer 34 (1998) 54-65
11. Goldhirsch A., Gelber R.D., Yothers G., et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr 30 (2001) 44-51
12. Yau T.K., Soong I.S., Chan K., et al. Clinical outcome of breast conservation therapy for breast cancer in Hong Kong: prognostic impact of ipsilateral breast tumour recurrence and 2005 St Gallen risk categories. Int J Radiat Oncol Biol Phys 68 (2007) 667-672
13. Chua M.S., Mok T.S., Kwan W.H., et al. Knowledge, perceptions, and attitudes of Hong Kong Chinese women on screening mammography and early breast cancer management. Breast J 11 (2005) 52-56
14. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
15. Bofin A.M., Ytterhus B., Martin C., et al. Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol 122 (2004) 110-119
16. Paik S., Bryant J., Tan-Chiu E., et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94 (2002) 852-854
17. Roche P.C., Suman V.J., Jenkins R.B., et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94 (2002) 855-857
18. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
19. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
20. Yaziji H., Goldstein L.C., Barry T.S., et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291 (2004) 1972-1977
21. Owens M.A., Horten B.C., and Da Silva M.M. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5 (2004) 63-69
22. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (2007) 118-145
23. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) Trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
24. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA 17. J Natl Cancer Inst 97 (2005) 1262-1271
25. Martin M., Pienkowski T., Mackey J., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352 (2005) 2302-2313
26. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
27. Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 369 (2007) 29-36